Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 1Phase 1 1

Status

Completed 3Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 116OTHER 105NIH 10NETWORK 7OTHER_GOV 2

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7

Conditions

Multiple Myeloma 6Recurrence 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
NETWORK × Interventional × pomalidomide × Clear all
NCT04667663 2026-04-13

CPD-DARA

Cancer Trials Ireland

Phase 1 Active not recruiting
16 enrolled
Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

European Myeloma Network B.V.

Phase 3 Active not recruiting
117 enrolled
Plasma cell

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Multiple Myeloma Research Consortium

Phase 1/2 Completed
103 enrolled
Plasma cell

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Multiple Myeloma Research Consortium

Phase 1/2 Terminated
14 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05066607 2024-03-06

IsAMYP

Intergroupe Francophone du Myelome

Phase 2 Unknown
46 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02185820 2023-07-03

CPD

European Myeloma Network B.V.

Phase 1/2 Completed
57 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡